Sharemaestro Newsreel

Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus

Neurocrine Biosciences (NBIX) stock dropped 10% despite strong Q2 2026 revenue and earnings, indicating the market is reacting to growth spending rather than current earnings. The company showed robust performance with INGREZZA and emerging products like CRENESSITY and VYKAT XR, but analysts are cautious …

ETFs Investing in Cumberland Pharmaceuticals Inc. Stocks

This article lists ETFs that hold Cumberland Pharmaceuticals Inc. (CPIX) stocks, providing investors with options for more accessible and lower-risk investment opportunities. It highlights one specific ETF, the Bridgeway Ultra-Small Company Market ETF (BUSM), detailing its market value, weight in CPIX, management style, and …

HUTCHMED (NASDAQ:HCM) Announces Earnings Results

Price to sales forward of Prestige Consumer Healthcare Inc. – NYSE:PBH

This article provides financial data for Prestige Consumer Healthcare Inc. (NYSE: PBH), specifically its price-to-sales forward metric. The content appears to be a financial snapshot from a trading platform, indicating market status and general financial information for the company.

Lantheus Holdings (LNTH) Pipeline Narrative Holds Firm, Does The Stock Look Fully Valued?

Lantheus Holdings (LNTH) shares recently closed at US$101, showing a strong year-to-date return of 50.14% despite a recent 9% dip. The company is considered 3% undervalued with a fair value of $104 per share, driven by an expanding radiodiagnostic pipeline including multiple new product …

Anika Therapeutics (ANIK) Stock Jumps As Profit Returns Sharpen Margin Focus

Sei Investments Co. Has $13.68 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Sei Investments Co. significantly increased its stake in Kiniksa Pharmaceuticals International (NASDAQ:KNSA) by 30.6% in the first quarter, now holding shares valued at $13.68 million. Institutional investors and hedge funds own over 53% of the company, and analysts maintain a "Buy" rating with an …

Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its …

Neurocrine Biosciences Q2 Earnings Call Highlights

Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. …

Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares

A director at Kiniksa Pharmaceuticals International, plc (KNSA), Cole G Bradley, reported two share dispositions on July 29, 2026. He sold 3,673 Class A Ordinary Shares for $81.43 each and gifted 4,500 shares to a donor advised fund. The transactions were not executed under …

Eton Pharmaceuticals Inc (ETON) Shares Fall 5.3% -- GF Value Says Still Overvalued

Eton Pharmaceuticals Inc (ETON) shares recently fell by 5.3%, making the stock significantly overvalued according to GuruFocus' GF Value™ estimate. The company, which is unprofitable, has a GF Score™ of 57/100, indicating average performance with strong growth potential but very poor valuation and momentum …

ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Friday

ANI Pharmaceuticals (ANIP) is scheduled to release its Q2 2026 earnings before market open on Friday, August 7th. Analysts project earnings of $2.01 per share and revenue of $260.13 million. The company surpassed analyst expectations in its previous quarter, reporting $2.05 EPS against an …

Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure

Amneal Pharmaceuticals (AMRX) reported a strong Q2 with increased revenue and adjusted EPS, leading to a raised full-year outlook. While the company is transitioning towards higher-margin biosimilars and injectables, investor concern centers on the sustainability of this profit momentum given increased capital expenditure and …

EVT.D.DX Price History for Evotec Se Stock

This article provides a comprehensive overview of the price history for Evotec Se (EVT.D.DX) stock on Barchart.com. It details how users can access and download historical daily, intraday, weekly, monthly, and quarterly price data, as well as information on corporate actions like splits and …

Cronos Group (TSX:CRON) - Stock Analysis

This article provides a detailed stock analysis of Cronos Group (TSX:CRON), a cannabinoid company, covering its valuation, growth prospects, financial health, and recent news. It highlights the company's market capitalization, forecasted earnings growth, and recent product launches and financial performance. The analysis also includes …

Tilray Brands climbs 8%, extending prior day's gains (TLRY:NASDAQ)

Tilray Brands (TLRY) shares climbed over 8% on Friday, extending a 5% gain from the previous day. This surge follows the global cannabis and beverage company's recent quarterly results. Despite the positive stock movement, investor concerns remain regarding recurring share dilution and management credibility.

Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S

Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling …

Aurora Cannabis Inc. stock falls Friday, underperforms market

Aurora Cannabis Inc. (ACB) stock dropped 1.41% on Friday, closing at $2.79, despite a positive overall trading day for the broader market. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains, indicating that Aurora Cannabis underperformed its peers. This decline ended …

Viatris Inc. stock falls Friday, underperforms market

Viatris Inc. (VTRS) stock fell 1.13% on Friday, closing at $17.56, despite an overall positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for Viatris …

Canopy Growth Number of Employees 2026 | Employee Count & Headcount Data

Canopy Growth Corp. (WEED) had approximately 1,140 employees worldwide as of March 2026, representing a 23.7% decline since 2023. The company is actively hiring with 106 active job postings in 2026, despite a 13.2% decline from 2025. Canopy Growth's workforce is primarily located in …

BioXcel Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. This action follows BioXcel's disclosure that a principal …

Opaleye Management (NASDAQ: HROW) discloses 6.44% Harrow ownership in latest filing

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, has reported a beneficial ownership of 6.44% in Harrow, Inc.'s Common Stock, totaling 2,400,000 shares. This disclosure was made in a SCHEDULE 13G/A filing and is based on 37,275,107 shares outstanding as of May …

Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

Liquidia Corporation (LQDA) is set to release its Q2 earnings on August 12, with strong sales and EPS estimates. The company has a positive earnings surprise history and its Yutrepia inhalation powder is a key growth driver, with impressive adoption rates. Despite competition, especially …

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Tilray Brands (NASDAQ:TLRY) shares rise, driven by growth in beverages and distribution

Tilray Brands (NASDAQ:TLRY) shares climbed by 6.4% to $4.47, fueled by significant growth in its beverage and distribution segments which accounted for 89% of revenue growth in the fourth quarter. While non-cannabis operations drove 71% of yearly revenue, cannabis contributed a larger share of …

Evotec stock trades steady as recent earnings and cash position frame the outlook

Evotec's stock performance is influenced by its solid revenue growth, recent net losses, and substantial cash reserves. The biotech company, listed on Xetra, saw double-digit revenue growth in fiscal 2025 but also reported a net loss due to high operating costs and investments in …

Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ)

Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) experienced significant declines after Novo Nordisk's (NVO) late-stage trial setback cast doubt on the mechanisms underlying their experimental heart disease therapies. The failure of Novo Nordisk's drug, which targeted hsCRP, raised questions about whether …

Analysts Have Conflicting Sentiments on These Healthcare Companies: Takeda Pharmaceutical Company (TAK), Align Tech (ALGN) and Conmed (CNMD)

This article summarizes recent analyst ratings for three healthcare companies: Takeda Pharmaceutical Company (TAK), Align Tech (ALGN), and Conmed (CNMD). Bank of America Securities maintained a Buy rating on Takeda, while giving Sell ratings to Align Tech and Conmed, highlighting conflicting sentiments within the …

Perrigo Co. PLC stock underperforms Friday when compared to competitors

Perrigo Co. PLC (PRGO) stock fell 1.94% on Friday, closing at $10.11, despite an overall positive trading session for the broader market. This marks the second consecutive day of losses for the company, while the S&P 500 and Dow Jones Industrial Average both saw …

Cronos Group Inc. stock falls Friday, underperforms market

Cronos Group Inc. (CRON) shares fell by 2.08% to $2.83 on Friday, despite a strong overall market performance where the NASDAQ Composite Index and Dow Jones Industrial Average both rose. This decline ended a two-day winning streak for the stock.

12 Health Care Stocks Moving In Friday's Intraday Session

This article identifies 12 healthcare stocks that experienced significant movement during Friday's intraday trading session. It highlights both gainers, such as Replimune Group and SCYNEXIS, which saw substantial increases, and losers like Karyopharm Therapeutics and Nuwellis, which experienced notable declines. The report provides specific …

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs (NASDAQ: BIOA) stock significantly dropped after Novo Nordisk's ZEUS trial results for ziltivekimab, an experimental drug, failed to reduce major adverse cardiovascular events. This outcome has led William Blair analyst Andy Hsieh to question the link between hsCRP reduction and cardiovascular protection, …

SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of SCYNEXIS Inc (SCYX), reporting its current financial score as 9.29, ranking 3 out of 155 in the Pharmaceuticals industry. The company's financial status is described as robust with high operating efficiency, despite a significant year-over-year decrease …

BioAge Labs Down Over 61%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

BioAge Labs, Inc. (BIOA) is experiencing a significant downturn, with its stock price at $9.61, representing a 61.33% decrease. This puts the company on track for its largest percentage decrease since December 2024 and its worst weekly and monthly performance since the same period. …

Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside

Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. …